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Highlights 
 Alopecia areata is a polygenic and multifactorial autoimmune disease characterised by 
non-scarring hair loss. 
 Autoreactive CD8+, CD4+, natural killer cells and plasmacytoid dendritic cells infiltrate 
around the hair follicles during the growth (anagen) phase. 
 Increased cytokine activity, particularly IFN-γ, results in disruption of the hair follicle 
immune privilege and premature termination of the anagen phase, followed by hair 
follicle atrophy and dystrophy in persistent disease.   
 
Abstract  
Alopecia areata is an autoimmune disease that results in non-scarring hair loss, and it is 
clinically characterised by small patches of baldness on the scalp and/or around the body. It can 
later progress to total loss of scalp hair (Alopecia totalis) and/or total loss of all body hair 
(Alopecia universalis). The rapid rate of hair loss and disfiguration caused by the condition 
causes anxiety on patients and increases the risks of developing psychological and psychiatric 
complications. Hair loss in alopecia areata is caused by lymphocytic infiltrations around the hair 
follicles and IFN-γ. IgG antibodies against the hair follicle cells are also found in alopecia areata 
sufferers. In addition, the disease coexists with other autoimmune disorders and can come 
secondary to infections or inflammation. However, despite the growing knowledge about 
alopecia areata, the aetiology and pathophysiology of disease are not well defined.  In this 
review we discuss various genetic and environmental factors that cause autoimmunity and 
describe the immune mechanisms that lead to hair loss in alopecia areata patients.  
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AIRE: Autoimmune regulator gene 
CNS: Central nervous system  
CXCL: Chemokine ligand 
CXCR: Chemokine receptor  
DC: Dendritic cell  
DNCB: Dinitrochlorobenzene 
DPCP: Diphenylcyclopropenone 
GZMB: Granzyme B 
HLA: Human leukocyte antigen  
ICI: Immune checkpoint inhibitors  
IFN-γ: Interferon gamma 
IgG: Immunoglobulin G  
JAK: Janus kinase  
MHC: Major histocompatibility complex 
MIF: Migration inhibitory factor 
NK: Natural killer cell  
NKG2D: Natural killer cell receptor D 
NKG2DL: Natural killer cell receptor D ligand 
PDC: Plasmacytoid dendritic cell  
ROS: Reactive oxygen species  
SNP: Single nucleotide polymorphism 
SOD: Superoxide dismutase  
STAT: Signal transducer and activator of transcription  
TCR: T cell receptor  
TGF-β: Transforming growth factor beta 
Th1/17: T-helper cell  
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TNF-α: Tumour necrosis factor alpha 









Alopecia areata is an autoimmune disease characterised by hair loss due to inflammatory 
responses that target the hair follicles. Incidence of disease in the USA and UK is about 2%, but 
the data varies for different populations and in different studies, with global incidence ranging 
from 0.57% to 3.8% [1–4]. In addition, some paediatric studies report a higher prevalence in 
children ranging from 10-50%, especially for those with a family history of alopecia areata, 
indicating a genetic basis for disease development [5–8]. 
The onset and progression of alopecia areata are unpredictable. Spontaneous hair re-growth is 
estimated to occur in 80% of patients within a year after the first incidence of alopecia, and 
relapse or progression to alopecia totalis and universalis can occur at any stage [1,2,4,9]. Due to 
the high percentage of patients that experience recovery, alopecia areata has been described 
as a short-term transient condition, although, based on genetic studies of sufferers and from 
mouse models the disease can also have a chronic phase which is more likely to progress to 
more advanced stages characterised by widespread hair loss [10–12].  
Although the exact cause of alopecia areata is poorly understood, genetics and immunity are 
confirmed as the most important contributors to disease. Infiltrates of T helper (Th) cells, 
cytolytic T cells, natural killer cells and plasmacytoid dendritic cells surround the lower part of 
the hair bulb during the anagen, the growth phase, where their autoimmune activities cause 
the collapse of the hair follicle immune privilege and alopecia (Figure 1) [10–18]. CD8+ cells 
recruit early in disease and are thought to be the main cell type that initiates alopecia areata 
[12,15,16]. Autoreactive Th1, Th17, NK and CD8+ cells produce IFN-γ which disturbs hair follicle 
functioning and causes disruption of the hair growth cycle, premature hair loss and inhibition of 
hair growth [11,12,14,15,19]. Type 1 interferons, chemokines (e.g. CXCL10) and cytokines (e.g. 
IL-12/23, TNF-α), have also been implicated in the maintenance of immune infiltrates and 
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disease manifestation [13,17,20]. Despite the autoimmune perturbations, the hair follicle is not 
destroyed, so the outcome is hair fall without scarring or permanent loss of tissue [11,12,14]. 
There are no therapeutics available for the prevention or cure alopecia areata. Various 
treatment options that target immune cells exist for the disease (Table 1), however the 
effectiveness varies between individuals and is dependent on the duration and stage of disease 
at commencement of treatment [21–23]. In addition, most treatments have a high relapse rate 
after the termination and are followed by negative side effects [21,23–25]. Sudden hair loss and 
disfiguration puts a psychological and economic burden on alopecia areata sufferers, and 
increases the risk of poor psychological health, low self-esteem and psychiatric morbidities [4].   
Therein, we discuss the link between genetics, the immune response and other external factors 
which when combined result in alopecia areata pathophysiology. Understanding the cellular 
and molecular mechanisms underpinning this disease is crucial to the informed development of 
effective therapeutics for the treatment and cure of alopecia areata. 
2. Inheritance of susceptibility for developing alopecia areata 
Alopecia areata is more likely to occur in patients with a family history of disease. Prevalence of 
disease in adult patients with a family history is estimated to range from 0% to 8.6% [1,2,4], and 
in children between 10% and 51.6% [5–8]. In addition, the occurrence of the disease in identical 
twins [26–28], siblings [29] and several generations of the same family [30,31], provides further 
evidence to support a genetic link. However, due to the frequency of the condition and 
variability in prevalence amongst individuals with a family history, the onset of alopecia areata 
is difficult to be predicted and does not follow any pattern. This suggests susceptibility to 
developing the alopecia areata is heritable, but that disease onset is likely to be environmental.  
3. Alopecia areata is a polygenic autoimmune disease 
Genetic studies in both mouse models and in the human population have shown that alopecia 
areata is a complex, polygenic condition [10–12,32]. Many of the genes which are strongly 
associated with alopecia areata are also involved in a variety of other autoimmune diseases 
such as type 1 diabetes mellitus, multiple sclerosis, psoriasis, and inflammatory bowel disease 
(Table 2) [11,33,34]. Hundreds of single nucleotide polymorphisms (SNPs) have been identified 
in alopecia areata patients, many of which are found  in genomic regions that control immune 
cell phenotypes, such as the activation and proliferation of regulatory T cells (Treg cells), 
cytotoxic T lymphocytes, interleukin expression and antigen presentation (Table 2) [11,13,35]. 
The human leukocyte antigen (HLA) region that encodes important key regulators in humans 
and the major histocompatibility complexes (MHC), has been identified as a major genetic 
contributor to the phenotype of disease [33,36–39]. Another locus on chromosome 6 which 
contains the genes encoding the natural killer (NK) cell receptor D (NKG2D; KLRK1) and its 
ligands NKG2DL3 (ULBP3) and retinoic acid early transcript 1L protein (RAET1L; also known 
as ULBP6), has been found to be implicated only in alopecia areata and not in other 
autoimmune diseases, suggesting a crucial role in this disease (Table 2) [11,12,34]. 
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These observations are further supported by findings in the C3H/HeJ mouse model, which is 
genetically susceptible to alopecia areata. The mouse equivalent of human leukocyte antigen 
(HLA) locus is the mouse histocompatibility locus H2, located on chromosome 17, which also 
contains several other orthologous genes which may be associated with human autoimmune 
alopecia [40]. C3H.SW-H2b/SnJ mice, that are C3H/HeJ congenic mice in which the H2k 
susceptibility locus is replaced with the H2b resistance locus, do not develop alopecia areata, 
further supporting the importance of HLA polymorphisms in disease [40]. Additionally, mouse 
models have identified another minor locus on chromosome 9 as being linked to alopecia 
phenotype, although underlying mechanisms have yet to be elucidated [40]. Similar to what is 
observed in humans, microarray studies on mouse models have identified around 42 genes 
which relate to inflammatory responses, expressed in early disease. An alteration in expression 
of 114 genes occurs in chronic stages of disease, with many of them regulating immunoglobulin 
responses [10]. Overall, similar to what is observed in humans, studies in C3H/HeJ mice have 
also shown the polygenic nature of the condition [10,32].  
Another gene associated with alopecia areata is the autoimmune regulator (AIRE) on 
chromosome 21, mutations of which result in polyendocrinopathy candidiasis ectodermal 
dysplasia syndrome (APECED), which is associated with multiple autoimmune disorders (Table 
2) [41–44].  Different polymorphisms of AIRE gene have also been associated with alopecia 
areata and universalis [41–43]. Patients with APECED have a 30% risk for developing  severe 
and early-onset alopecia areata [41]. In addition, SNPs of AIRE have also been identified in 
people with alopecia areata without APECED, showing that they can be a major component of 
the genetic risk for developing the disease [43]. This gene encodes a protein which plays an 
important role in immunity by regulating the expression of autoantigens and negative selection 
of autoreactive T-cells in the thymus (NCBI, Gene ID: 326). The involvement of this gene in 
alopecia areata is supportive of the strong autoimmune nature of this disease [41,44].   
4. Immune responses and cells involved in Alopecia areata. 
Alopecia areata onset and progression is strongly influenced by the immune system. Skin 
biopsies of affected patients show lymphocytic infiltrates in and around the lower part of the 
hair follicle in the anagen (hair growth) phase [12,14]. The autoimmune activity at the site of 
the hair follicle has been linked to the disruption of the hair cycle and hair loss [4,11,12,45] In 
many cases alopecia areata coexists with other autoimmune diseases, such as thyroid disease, 
celiac disease, rheumatoid arthritis, and lupus erythematosus, with which can share the 
pathways that initiate autoimmunity  [4,12,46]. 
Based on the genes identified as being dysregulated in alopecia areata, it is suggested that both 
the innate and the adaptive immunity contribute to the disease phenotype [10–12]. 
Upregulation of genes that control antigen presentation and co-stimulation suggests a role for 
dendritic cells and T cells in the development of antigen-specific immune mediated pathology. 
Many other genes such as NKG2D implicate cytolytic T cells and natural killer cells (NK), 
whereas the upregulation of immunoglobulin genes in late disease as seen in mouse models 
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implicates B cells and antibody production [10,11]. Predictions based on gene analysis can be 
confirmed in patients and mouse models. CD4+ T cells are located alongside CD8+ T cells in the 
hair follicle during the anagen phase in alopecia affected skin of human and mice [14]. 
Monoclonal antibody depletion of CD4+ and CD8+ cells in a murine model of chronic alopecia 
areata has been shown to improve hair regrowth [10]. In addition, anti-hair-follicle IgG 
antibodies are present in patients with alopecia areata, and reducing them by means of topical 
immunotherapy causes hair regrowth [47].  
4.1. CD8+ lymphocytes as the main contributors in disease 
CD8+NKG2D+T cells (cytotoxic T cells) have been identified as major contributors of hair loss in 
alopecia areata and the first to infiltrate around the hair follicles (Figure 1) [12,15,16,48]. These 
cells are necessary and sufficient for the induction of the disease in mouse models [12,15]. The 
gene encoding NKG2D is upregulated in alopecia areata patients, and associated ligands 
NKD2DL3 and RAET1L are found overexpressed in the hair follicle cells of alopecia patients but 
not in unaffected individuals or those affected by any other inflammatory scalp disease [11]. In 
addition, Cd8a transcripts, the alpha component of the CD8 costimulatory molecule on CD8+ T 
cells, increase early after engraftment of alopecia areata skin on mice, suggesting CD8+ T cells 
recruit early in disease [14]. Similarly, transcriptional profiling of mouse and human affected 
skin has revealed gene expression signatures indicative of cytotoxic T cell infiltration, such as 
increased production of interferon-γ (IFN-γ) and γ-chain (γc) cytokines and receptors which are 
known to promote the activation and survival of IFNγ–producing CD8+NKG2D+ effector T cells 
(Figure 1) [15]. When IFN-γ, interleukin-2 (IL-2) or interleukin-15 receptor beta (IL-15Rβ) are 
inhibited, the disease development is prevented by reducing the accumulation of 
CD8+NKG2D+ T cells and the dermal interferon response on the skin of mouse models [15].  
There is evidence that the CD8+ T cells attack the hair follicle using Granzyme B (GZMB), a 
cytotoxic molecule produced by effector CD8+ T cells (Figure 1).  In hair follicles of humans 
affected by alopecia areata, Granzyme B (GZMB) and cytotoxic granule associated RNA binding 
protein I (TIA1) are both elevated [13]. In alopecia affected C3H/HeJ mice however, only 
Gzmb transcripts are increased, with no Tia1 expression, suggesting that GZMB secretion may 
be more important for CD8+ T cell driven pathology [14].  
4.2. Role of the Th17 and Treg cells in alopecia areata 
CD4+ subtypes Th17 (CD4+IL-17A+) and Treg cells are found to contribute to autoimmunity in 
alopecia areata [19,49]. In alopecia areata patients, Th17 cells are infiltrated in dermis and 
around the hair follicles, and can be involved in cell-mediated autoimmunity [19]. These cells 
are also implicated in psoriasis and vitiligo, two autoimmune diseases reported as comorbidities 
of alopecia areata [4,12,19]. In addition, alopecia areata sufferers have an imbalance between 
Th17 and Treg cells, with Th17 levels in blood exceeding the Treg levels during active stages of 
disease [49]. For more severe alopecia areata however, Treg cells exceed the Th17 [49]. Such 
imbalance between Th17 and Treg cells in alopecia areata can result in inflammation and 
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autoimmunity through similar pro-inflammatory mechanisms reported in other autoimmune 
diseases [50].   
4.3. Plasmacytoid dendritic cells: a link between the innate and adaptive responses? 
Plasmacytoid dendritic cells (PDC) have been identified in infiltrates around the hair follicles of 
alopecia areata patients [17].  These are specialized dendritic cell populations with plasma cell 
morphology, express CD4, CD123, HLA‐DR, blood‐derived dendritic cell antigen‐2 (BDCA‐2) and 
Toll‐like receptor (TLR)7 and TLR9 within endosomal compartments [17,51].  The PDCs are a link 
between the innate and adaptive immunity by controlling the function of myeloid DCs, T, B and 
NK cells [17,51]. They are absent from normal skin but can infiltrate upon injury or pathology, 
and are linked to inflammation towards infections, as well as autoimmunity in diseases such as  
lupus and psoriasis [17,51], two comorbidities of alopecia areata [46]. Upon activation they 
produce large quantities of type I interferons (IFN‐α/β) [51], which have been implicated in  
alopecia areata for inducing  CD4+, CD8+ and NK responses towards the hair follicles (Figure 2) 
[13]. How they recruit at the hair follicles is still undetermined, but it has been suggested that 
they could be the link between the innate and adaptive immune responses  that eventually 
leads to hair loss in alopecia areata [17].  
4.4. Cytokine activity in alopecia areata 
Interferon gamma (IFN-γ) has been implicated in the pathogenesis of alopecia areata by 
interfering with the maintenance of the immune privilege of the hair follicle (Figure 1). The 
immune privilege of the hair follicle is usually maintained at the anagen phase by 
downregulation of expression of MHC class I molecules [16,52,53] and expression of NK and 
CD8+ cell inhibitors such as macrophage migration inhibitory factor (MIF) and transforming 
growth factors (TGF) β1 and β2 [12,16,53,54]. IFN-γ causes collapse of the  hair follicle immune 
privilege by inducing ectopic expression of MHC molecules and ligands that stimulate NK-cell 
receptors (NKG2D) in the anagen hair bulb (Figure 1) [11,12,16,55,56].  Upregulation of these 
molecules on the hair follicle cells is responsible for the autoreactivity seen in alopecia areata 
(Figure 1) [12,16,53]. Furthermore, alopecia areata susceptible C3H/HeJ mice are protected 
from disease following deletion of the IFN-γ gene, providing evidence of the important role of 
this cytokine in disease development [57].  
In addition, IFN-γ induced JAK/STAT signalling can interfere with the hair growth cycle.  
JAK/STAT signalling is suppressed in hair follicles during the anagen [58,59],  as such signalling  
can inhibit proliferation and activation of hair stem cells [58], and  result in reduction of 
angiogenesis [60]. Therefore, IFN-γ induced JAK/STAT signalling could be the reason of the 
premature termination of the anagen phase in alopecia areata [16,53].  Inhibition of JAK/STAT 
signalling has shown to reverse alopecia symptoms and induce hair growth [59].  
Tumour necrosis factor-alpha (TNF-α) has been  found to be increased  in  the serum of patients 
with alopecia areata and the extensive forms totalis  and universalis compared to healthy 
control groups [61,62]. TNF-α is a proinflammatory cytokine involved in infections and 
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inflammatory disorders, and it is also a signalling molecule involved in differentiation and 
proliferation of cells [63].  This cytokine has shown to have both damaging and protective effect 
in a variety of autoimmune disorders such as rheumatoid arthritis, multiple sclerosis and 
systemic lupus [64], and certain polymorphisms of TNFA have also been implicated in alopecia 
areata [65] ( Table 2).  
In alopecia areata skin TNF-α originates from T cell infiltrates [18].  The cytokine has shown to 
have anti-proliferation effect on epithelial cells and keratinocytes [18,61], and in ex vivo hair 
follicles the cytokine has disturbed the hair cycle  and induced catagen morphology [20]. This 
means that the increased TNF-α in alopecia areata patients could be responsible in addition to 
other cytokines like IFN-γ for the manifestation of disease.  However, blocking TNF-α has not 
only been ineffective to treat alopecia areata, but such process has also induced the disease 
[66–68]. Interestingly, some studies have reported that TNF-α can inhibit MHC class I 
upregulation caused by IFN-γ in hair follicle cells [69,70]. In addition, TNF‐α is known to 
suppress the development of PDCs that produce high IFN‐α levels which are responsible for the 
coordination of CD4+, CD8+ and NK cell responses [17,71].  It has been suggested that the 
antagonism of TNF-α leads to alopecia areata by allowing uncontrolled IFN‐α production from 
PDCs [17] , as well as by interfering with the protection the cytokine could provide against IFN-γ  
upregulation of MHC class I [69,70].  It can therefore suggested that TNF‐α could be elevated in 
alopecia areata patients to provide some protection from IFN‐α and IFN-γ responses [17,69,70], 
but that nevertheless interferes with the keratinocyte differentiation and causes hair cycle 
disturbance (Figure 2) [20].  
In addition, mouse models have shown an upregulation of CXCR3 and CXCR3 ligands, CXCL9 and 
CXCL10, around the hair follicle during early development of alopecia areata, resulting in the 
recruitment of lymphocytes and initiation of autoimmunity at the site (Figure 1) [14].  Mx2, the 
mouse homolog of human myxovirus protein A (MxA), an IFNγ-related protein, has also shown 
to be upregulated. These observations are consistent with results from human studies where 
CXCR3 and MxA are found increased around the hair follicles of alopecia areata sufferers [13].  
CXCR3 and ligands CXCL9, CXCL10, and CXCL11, all of which are strongly induced by IFN-γ, are 
associated with many other autoimmune diseases including, rheumatoid arthritis, type I 
diabetes, psoriasis and systemic lupus erythematosus (Table1) [14,72]. CXCR3 is expressed 
primarily on Th1 CD4+ T cells, CD8+ T cells, NK and NKT cells, while CXCR3 ligands are secreted 
by many tissue resident cells including dendritic cells. Secretion of these chemokines results in 
recruitment of lymphocytes and enhanced Th1-mediated and natural killer cell (NK) mediated 
immune responses, with a positive feedback loop driven by further IFN-γ produced by the Th1 
and NK effector cells [72,73]. The recruitment of lymphocytes at the hair follicle can result in 
the onset of alopecia areata, whereas the positive IFN-γ feedback loop can explain the duration 




Interestingly, the proinflammatory environment does not destroy the hair follicle tissue so the 
possibility remains for rescue of physiological function and hair growth [4,11,12,45]. The 
autoimmune responses disrupt the hair growth cycle by prematurely terminating the anagen 
phase forcing the hair follicle into the catagen phase that is followed by hair loss [12,16,53]. The 
hair follicle experiences dystrophy, but not complete destruction [16,53]. In addition, 
involvement of STX17, a gene involved in premature hair greying, and ACOXL/BCL2L11 that 
control apoptotic and autophagy pathways, may indicate intrinsic issues related with the hair 
follicle cells that can result in loss of function independent of immune cell involvement [11,34]. 
This is indicative that the mechanisms by which the hair follicles are impaired in alopecia areata 
are not fully understood and more research is needed to elucidate the cellular and molecular 
events within the hair follicle before and during disease onset.  
 
Figure 1: Immune responses in the hair follicle during development of alopecia areata. The hair follicle 
cells upregulate expression of MHC molecules, NKG2D (A) and chemoattractants (G). CD8+ T cells 
expressing NKG2D become effector cells upon binding MHC class I-antigen complex and NKG2D ligand 
on hair follicle cells (B). Effector CD8+ cells are maintained by the production of IL-2 and IL-15 (C), and 
produce Granzyme B (D) and IFN-γ (E). Granzyme B may promote cell lysis (D), but evidence suggests 
that the hair tissue is not fully destroyed in alopecia areata. IFN-γ which accumulates at the site of 
inflammation, signals through the JAK-STAT pathway and can induce further abnormal expression on 
hair follicle cells and impair the hair growth cycle (F). CD4+ and NK cells are recruited to the hair 
follicle (H), as a result of chemokine expression by the hair follicle cells (G). NK cells also express the 
NKG2D and may attack the hair follicle cells upon binding the NKG2D ligand in similar manner as the 
CD8+ cells (I).  Effector CD4+ and NK cells both produce IFN-γ (J), which then further induces the 






Figure 2: Plasmacytoid dendritic cells (PDC) are a source of type 1 IFNs in alopecia areata (A). They 
enhance CD8+, CD4+ and NK cell activities and IFN-γ production (B).  Lymphocytic infiltrates also 
produce TNF-a, a cytokine upregulated in alopecia areata patients. TNF-α can disrupt the 
development of keratinocytes and epithelial cells and thus affect the hair growth (C). However, it can 
also have protective effects as it has shown to inhibit IFN-γ induced MHC class I upregulation in hair 
follicle cells (D), as well as regulating IFN-α production by inhibiting PDC activity. 
 
5. Other factors involved in initiation and progression of autoimmune Alopecia areata 
In addition to the genetic predisposition for developing alopecia areata, there are different 
environmental factors that could initiate autoimmunity and disease. Different studies discussed 
further in this review indicate that alopecia areata is a multifactorial autoimmune disease with 
genetic and environmental aetiology (Figure 3). 
5.1. Oxidative stress may damage hair follicles and initiate disease. 
Alopecia areata and other skin diseases have shown to be affected by oxidative stress [74,75]. 
In alopecia areata patients, single nucleotide polymorphisms of antioxidant-encoding genes 
PRDX5 and ALDH2 have been identified to be associated with the disease phenotype, both 
hypothesised to interfere with the growth cycle of hair [11,34]. Furthermore, alopecia areata 
sufferers have higher levels of circulating malondialdehyde, a product of lipid peroxidation, and 
increased antioxidant activity of superoxide dismutase (SOD), when compared to healthy 
individuals [76]. In one study, 32% of patients suffering from alopecia areata were sero positive 
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for reactive oxygen species (ROS)-damaged SOD antibodies [75]. This study suggests that 
oxidative stress and SOD damage may be involved in compromised hair follicle function and 
disease progression. However, the oxidative processes in hair follicle cells are not well 
identified, and contradicting results can be found. To explain the accumulation of ROS, one 
particular regional study investigated polymorphisms of SOD2 (MnSOD Ala-9Val), linked to 
increased H2O2 accumulation and increased ROS production [77], and GPX1 (GPx1 Pro 198 Leu), 
which impacts the optimal antioxidant response of GPx1, but found no association with 
alopecia areata [78]. This however, does not completely rule out that impairment of 
antioxidant function is responsible for increased oxidative damage, and expanding the range of 
antioxidants and participant populations is required to further elucidate.  
In addition, ROS can be produced in response to different factors such as cigarette smoking, 
consumption of alcohol, prescription of nonsteroidal anti-inflammatory drugs, chronic 
infections, and inflammatory disorders [79]. Therefore, the presence of ROS in patients with 
alopecia areata can also be a result of treatment, infections, and/or chronic inflammation 
caused by the immune responses and other comorbidities. 
5.2. Psychological stress as trigger of Alopecia areata? 
The relationship between psychological stress and the development of alopecia areata is 
controversial.  Different studies have shown no influence of such stress in the onset of the 
disease [80,81]. Other studies however have shown that psychological stress can be a 
precipitating or aggravating  factor for the onset of alopecia areata, as many patients have 
reported  pre-onset stressful events compared to  healthy control groups  [82,83]. Some of 
these events go back years and as far as childhood, giving the disease a psychosomatic nature 
[83,84].However, the psychosomatic aspects are also controversial as other studies have failed 
to record stress episodes from alopecia areata patients not late from the onset [85,86].  Since 
most studies have gathered data on patients with more than six months [83] to years [84] from 
the onset, the reliability is low as distant psychological events could have been linked with 
alopecia areata after the hair loss, in addition to the inability to recall events correctly after 
months of stressful living with the disease [86]. 
From a biological point of view, there is certain evidence to suggest role of the central nervous 
system (CNS) and acute stress in alopecia areata pathology [87,88]. Both corticotropin releasing 
hormone receptors (CRHRs) and adrenocorticotropic hormone (ACTH) are upregulated in the 
skin of alopecia areata patients in response to acute emotional stress [87,89,90]. Immune cells, 
such as T and B cells, DC and macrophages  can interact with the nervous system, particularly 
with the cholinergic system,  as they express components such as muscarinic and nicotinic 
acetylcholine (ACh) receptors (mAChRs and nAChRs, respectively), choline acetyltransferase 
(ChAT) and acetylcholinesterase (AChE) [91,92].  In acute stress the upregulation of hormones 
such as acetylcholine (ACh) can lead to modulation of immune cells functioning as well as 
upregulation of TNF-α, IFN-γ and IL-6 secretion [91,92], and it can be speculated that in alopecia 
areata predisposed patients that could result in inflammation and onset of disease.   
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More evidence on the interaction of the CNS with the hair follicles is observed in anatomical 
abnormalities of the nerve supply of alopecia areata affected hair follicles [87,93]. In addition, 
the substance P (SP), a neuropeptide, in ex vivo hair follicles induces upregulation of nerve 
growth factor (NGF) and its apoptosis- and catagen-promoting receptor (p75NTR), as well as  
MHC class I and beta2-microglobulin [94]. Such upregulation results in disruption of the hair 
cycle by inducing premature catagen development, as well as collapse of the hair follicle 
immune privilege [94], two of the characteristics features of alopecia areata [44,53]. Therefore, 
although controversial, the influence of the psychological stress in the onset of alopecia areata 
is possible.  
5.3. Infectious agents are linked to onset and progression of alopecia areata.  
A link exists between Helicobacter pylori infection and alopecia areata [95,96]. The coexistence 
of H. pylori infection in different autoimmune conditions, many of which affect skin, has 
suggested that the bacterium may impact upon pathology [97]. The association of H. pylori and 
alopecia areata is controversial. One study found higher prevalence of H. pylori infection in 
patients with alopecia areata [95], while other studies have failed to identify such association 
[98,99]. In one case however, a single adult patient that had been diagnosed with both alopecia 
areata and helicobacter pylori, was cured of both diseases after treating the infection with 
antibiotics [96].  Helicobacter pylori infection may cause alopecia areata by inducing Th1 and 
Th17 cell responses, which result in inflammation characterised by IFN-γ secretion [100]. In 
addition, the bacterium has shown to induce Treg expansion at the site of infection [100,101], 
and this may cause the disruption in Th17/Treg balance seen in alopecia areata sufferers [49], 
although the exact mechanisms are yet to be elucidated.  
Viral agents have also been associated with the disease. Alopecia areata incidence was 
increased in patients who were infected by the swine flu virus during the outbreak of 2009-
2010 [102]. Upon Influenza infection, overproduction of IFN-γ with high fever can result in 
induction of Th1 immune responses [102,103], collapse of hair follicle immune privilege and 
alopecia areata. Cytomegalovirus (CMV) has been reported to trigger alopecia areata [104], 
although the causative link is controversial and not all studies have agreed on such association 
[105,106]. The disease has also been reported to be triggered in patients with infectious 
mononucleosis caused by Epstein–Barr virus [107].  
Low incidence of alopecia areata has also been observed shortly after vaccinations against a 
variety of human pathogens including, hepatitis B virus [108], Clostridium tetani [109], herpes 
zoster virus [110], Japanese encephalitis [111] and human papillomavirus [112]. The disease in 
these cases may be a result of a hypersensitive reaction to vaccines in patients that are 
genetically predisposed. This response can induce the activation of IFNγ-producing cells, 
including the autoimmune cells, during antigen presentation in the secondary lymphoid tissues 
of alopecia areata predisposed patients.  
5.4. Immune checkpoint inhibitors used in cancer treatments  
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Immune checkpoint inhibitors (ICI), such as anti-programmed cell death-1 (PD-1) and anti-
programmed cell death ligand-1 (PD-L1), have shown exceptional activity in many cancers 
[113,114].  Many cancer cells evade the immune system by overexpression of PD-L1, which 
binds to PD-1 on T cells and suppresses their activity [113,115]. Therefore, by inhibiting such 
interaction the  anti-tumour immune responses are enhanced [113,115]. Nivolumab and 
pembrolizumab are IgG antagonist antibodies against PD-1, while avelumab, atezolizumab and 
durvalumab are IgG antibodies against PD-L1 [113]. There is a wide range of adverse cutaneous 
morphologies seen with PD-1/PD-L1 inhibitors such as generalized pruritus, vitiligo, 
maculopapular lesions,  lichenoid skin eruptions and non-scarring alopecia areata [113]. 
Recently, it has been shown that alopecia areata is a common side effect of such 
immunotherapies, particularly nivolumab [116]. In addition, this antibody has been reported to 
cause a strange case of persistent curly hair in an individual that never had such feature [117].  
Although the mechanism of action that leads to alopecia areata in ICI treatments is yet to be 
elucidated, it has been suggested that the re-activated T cells might cause inflammation and 
cross-react with dermal antigens [113,118].  Another suggestion is that since PD-1 pathways are 
involved in tolerance to self-antigens and autoimmunity [119],  then ICI treatment may allow 
development of autoimmunity by “unmasking” pre-existing  autoreactive cells and/or  amplify 
their response [118]. The observation that such treatments cause alopecia areata is another 
example of the strong immunological roots for the disease.  
5.5. Microbiota and diet. 
The influence of the human microbiota in health and disease is an exciting and rapidly 
developing field of biological research. There is a potential link between microbiota and 
alopecia areata. C3H/HeJ alopecia areata mouse models are also by inheritance susceptible to 
developing colitis [120]. As a matter of fact, ulcerative colitis has been reported as a 
comorbidity of those suffering from alopecia areata [121]. The host-microbe relationship is 
important for overall health and well-being, and disruption thereof has been linked with several 
inflammatory diseases [122]. Evidence suggests that genotype determines the early microbial 
colonizers of the infant gut, and that there is a strong link between genetic profile and the 
microbiota [123,124]. This can suggest that genes that are related to alopecia may also affect 
the gut colonization with certain microbes that can be more immunogenic and induce chronic 
inflammation. For example, in celiac disease, the genes allow colonization of the gut with 
microbes that induce a Th1 response followed by IFN-γ production [124]. Since alopecia areata 
patients are sensitive to IFN-γ responses (Figure 1), then exposure to Th1-like inflammation for 
prolonged periods of time, could lead to initiation of autoimmunity. 
In addition, epidemiological studies suggest a geographical influence on the life-time risk for 
developing alopecia areata, associated with diet [125]. For example, in the US where the 
majority of people follow a western diet, the lifetime risk for alopecia areata is estimated 
around 1.7% [4,126], whereas in Japan where people follow  soya-based eastern diets,  the life 
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time risk  is no more than 1 % [125]. However, Japanese people living in the US have a similar 
lifetime risk as the rest of American population [127]. These geographical differences have been 
linked to differences in diet, and hypotheses have been raised that a soy-rich diet characteristic 
of eastern Asia can delay the onset of alopecia areata or reduce susceptibility [125].  Apart from 
these observations in humans, soy-rich diet has been reported to interfere with development of 
alopecia areata in mouse models [125,128].  Even though the benefits of such diets are thought 
to be related to compounds found in soya [125], since there is a strong link between dietary 
nutrients and microbiota [129], the gut bacteria may also have a role in modifying the onset of 
alopecia areata.            
                                                                                     
                                                                                                                
Figure 3: Different factors are involved in the initiation of autoimmune alopecia. Alopecia areata 
results when the immune privilege of the hair bulb during the anagen is lost and autoreactive 
infiltrates target the hair follicle cells.  These events can be strongly influenced by the 
genetics. However, different environmental factor can initiate disease in genetically 
predisposed patients by inducing Th1-like inflammatory responses, interfering with hair 
follicle cells and disrupting the hair growth cycle.   Oxidative stress and inflammation triggered 
in the vicinity of the hair follicles in comorbidities or infections could result in impairment of 
the immune privilege and initiation of autoimmunity. Other factors like pathogens, microbiota 
and immune checkpoint inhibitors could enhance autoreactive cell activity and decrease their 
selection during maturation. However, the mechanisms at which these factors lead to 
autoimmunity are poorly understood at the present. Better understanding of how they 
influence disease could help prevent and treat alopecia areata.  
6. Treatments for alopecia areata are focused at targeting the autoimmunity  
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Genetic and immunological observations suggest a strong cell-mediated response for the onset 
and progression of disease, therefore representing an attractive target for therapeutics.  In fact, 
some of the most successful therapies that exist for alopecia areata target the immune cells 
and their activity (Table 1). The mechanism of action for many of these drugs involves inhibition 
of cytokine signalling (e.g. JAK inhibitors), altering the Th1-type immune responses (e.g.  
contact sensitizers) and suppression of immune cell activity (e.g. corticosteroids) [15,21,130–
132].  
6.1. Inhibitors of IFN-γ induced signalling 
Janus kinase (JAK) inhibitors are considered a potential therapeutic approach for alopecia 
areata, and many trials have shown positive effects of their administration in autoimmune 
alopecia patients [12,15,59,131,132]. JAK family protein tyrosine kinases (Figure 1) are 
downstream effectors of the IFN-γ and γc cytokine receptors that are expressed in the immune 
cells and hair follicle cells [12,15,23].  Inhibition of JAK/STAT signalling can help in alopecia 
areata by reducing the negative effects of IFN-γ on hair follicle cells, as well as by interfering 
with the maintenance of lymphocytic infiltrates during the anagen [59]. In addition, studies 
have shown that JAK/STAT signalling is involved in the hair cycle, and it is upregulated in the 
catagen and telogen phases, but suppressed in the anagen [58,59].  Inhibition of the JAK/STAT 
signalling  has shown to promote hair growth by stimulating the activation and/or proliferation 
of hair follicle stem cells [58] and inducing angiogenesis [60], characteristic processes occurring 
during the anagen phase when the hair is growing  [59,60].  
Ruxolitinib is a selective inhibitor of JAK1 and JAK2 [59]. In addition, ruxolitinib has been shown 
to have anti-inflammatory effects, which are thought to be due to interruption of the IL-17 
signalling axis [133]. Decreased levels of circulating inflammatory cytokines such as TNF-α and 
IL-6  have been observed in  mice treated with ruxolitinib [134].  Different studies have shown 
varying results of  effectiveness of ruxolitinib in alopecia areata patients, and  further 
investigation is needed for optimisation of  treatments involving this drug [59]. 
Tofacitinib is a JAK1 and JAK3 inhibitor approved for the treatment of rheumatoid arthritis, and 
it has recently shown to be successful for treating alopecia areata [135–137]. Tofacitinib 
treatment has resulted in hair growth and its mechanisms have shown to involve decreasing 
clonally expanded  CD8+ T cell populations in alopecia areata scalp [48], reducing chemokine 
CXCL10 levels [136], and promoting angiogenesis by upregulation of vascular endothelial 
growth factor (VEGF) [60].  However, the drug has failed to completely remove CD8+ cells from 
affected skin or blood, which could explain the relapse after the treatment stops [48]. Topical 
tofacitinib and ruxolitinib have also shown to be effective and cause hair growth in alopecia 
areata patients [137].  Despite the effectiveness of tofacitinib, more investigation is needed as 
results have shown to vary based on disease severity and treatment progression [24].  
6.2.  Contact sensitizers  
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Topical immunotherapy is another method of treatment which utilises an allergen known as 
Diphenylcyclopropenone or diphencyprone (DPCP) to induce hair growth in both adults 
[25,130] and children suffering from alopecia areata [138]. The response rate to DPCP varies 
from 17% in patients with alopecia totalis or universalis, to 60% to 100% in patients with early 
patchy alopecia areata, making it a very successful treatment when applied early in disease 
[130]. The mechanisms of action of DPCP are not fully understood, but it is speculated that the 
drug can redirect the cellular responses in autoimmunity through antigen competition and 
reduction of anti-hair-follicle antibodies [23,47,139].   
Another contact sensitizer used as topical immunotherapy is dinitrochlorobenzene (DNCB) 
[140]. In a recent report, 50.98% of patients responded to DNCB, compared to 34.43% who 
responded to DPCP [140].  In the past DNCB has also shown positive results when tested for 
alopecia areata, totalis and universalis, and for different disease duration periods (Table 1) [22]. 
The negative aspect of DNCB that makes it less favourable than the DPCP is that it has shown to 
be strongly mutagenic  by increasing in the exchange of chromosomal material between the 
sister chromatids in human skin fibroblasts [141]. The mechanisms of action by which DNCB 
reverses alopecia areata are unknown, but similar to DPCP, it may involve antigen competition.  
6.3. Regulation of cytokine activity  
Another treatment option, regulating the cytokine activity in alopecia areata, has proven to be 
complex and controversial regarding effectiveness. Attempts to treat alopecia areata with 
biological, immunosuppressive, and anti-psoriasis drugs which target specific molecules such as 
TNF-α (adalimumab, etanercept, infliximab), CD2 (alefacept) or CD11a (efalizumab) , have been 
unsuccessful [142]. 
Ustekinumab is an IgG antibody against the p40 subunit of IL- 12 and IL-23 which inhibits their 
activity and subsequent induction of IFN-γ, IL-17A, TNF-α, IL-2, and IL-10 secretion from the 
immune cells [143–145]. The IL-12 and IL-23 cytokines are characteristic of Th1 and Th17 
responses which are linked to alopecia areata and other autoimmune skin conditions such as 
psoriasis and vitiligo, so inhibiting them can be therapeutic in autoimmunity [144–147].  
However, despite the theory, inhibition of these cytokines has shown controversial results.  One 
study observed that alopecia areata coexisting with psoriasis, was improved after ustekinumab 
treatment [147]. Other studies however, have shown that while such treatment is effective for 
psoriasis, it has an negative effect for inducing alopecia areata even in patients without family 
history of disease [144,145]. The authors of these studies have hypothesised that the hair loss 
observed during  ustekinumab  and anti-psoriasis treatment could  be because the immune 
system during  severe psoriasis inhibits development of alopecia areata, in patients who would 
otherwise have the disease [144,145]. Successful therapy of psoriasis may act as an immune 
switch which induces the development of alopecia areata in these patients [144]. 
7. Conclusion  
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Alopecia areata is an autoimmune disease with genetic and environmental aetiology.  The 
disease manifests when the immune privilege of the hair follicles is impaired and immune cells 
infiltrate around the hair bulb during the anagen phase. The autoreactive immune responses 
lead to the disruption of the hair cycle by prematurely terminating the anagen followed by hair 
follicle atrophy and dystrophy in persistent disease. However, the hair follicle tissues are not 
destroyed, so reversing alopecia areata remains as a possibility.  Treatment of alopecia areata is 
focused at inhibition of autoimmunity, by targeting cytokine signalling and the immune cell 
infiltrates, which are the major contributors to disease.   
The prevention of autoimmune alopecia is challenging because of the multifactorial aetiology 
which may require difficult genetic testing and strict avoidance of environmental factors, the 
effect of which is yet not fully understood. Better diagnosis of comorbidities and identification 
of initiating factors can lead to patient-specific therapies that can be more effective that the 
current ones. In addition, alopecia areata patients may also need treatments for the 
psychological aspects that are associated with the disease, such as clinical depression. This will 
reduce the burden from patients and improve their overall well-being.  Ongoing research will 
provide deeper understanding of the underlying mechanisms that lead to development of 




Table 1: Current treatments for alopecia areata* 
Therapy Administration Effectiveness  Side effects 
Topical corticosteroids  
(e.g. Clobetasol propionate) 
Topical foam or 
cream 
Inconclusive. It is reported 
that >25% of patients 
experience more than 50% 
hair growth, but conflicting 
data exist[21] 









Injected in the skin 
Inconclusive. More 
effective in adult patients. 
Treatment must stop if no 






Topical foam or 
cream 
Response rate:  
38% for 1% Minoxidil 





Topical cream Response rate 
75% in patchy AA  








Staining of skin 
Diphenylcyclopropenone 
(DPCP) 
Topical cream Cosmetic regrowth in: 
17.4% of patients with 
alopecia totalis/universalis, 
60.3% with 75–99% AA, 
88.1% with 50–74% AA, 
100% with 25–49% AA. 
Severe irritation, 
Lymphadenopathy 
Facial and scalp 
oedema,  









Topical solution Hair growth (%) [22]: 
10–90% hair loss of <5 
years duration: 90% 
10–90% hair loss of >5 
years duration: 60% 
Alopecia totalis of <5 years 
duration: 70% 
Alopecia totalis of >5 years 
duration: 40% 
Alopecia universalis of <5 
years duration: 50% 
Alopecia universalis of >5 






Psoralen plus ultraviolet A 
(PUVA) 
Phototherapy Inconclusive. Hair regrowth 
is reported in 41.5% of 





Janus kinase (JAK) inhibitor 
(Ruxolitinib) 
Oral intake Response rate: 75% 
Regrowth in >50% of 
patients 
Relapse: 3 weeks after 
treatment stops 





Janus kinase (JAK) inhibitor 
(Tofacitinib) 
 
Oral Intake  Regrowth in >50% of 
patients 
Relapse: expected after 3-6 






Janus kinase (JAK) inhibitor 
(Ruxolitinib, Tofacitinib) 
Topical Solution Growth in >50% of patients 







(e.g.  prednisolone) 
Oral intake Response rate: 82% 


















Oral intake alone 








N.B.*: Treatments that are usually applied in patients suffering from alopecia areata [21–
23,59,132,135–137]. 
 
Table 2: Genes with strong association with alopecia areata* 
Location Genes associated with 
Alopecia areata 




NOTCH4 Haematopoiesis, T cell 
differentiation 
T1D, RA, MS 
C6orf10 Unknown function in vivo T1D, RA, PS, GV 
BTNL2 Co-stimulation  T1D, RA, UC, CD, SLE, MS  
HLA-DRA Antigen presentation (MHC II) T1D, RA, CeD, MS, GV 
HLA-DQA1 Antigen presentation (MHC II) T1D, RA, UC, CD, SLE, MS, 
CeD, GD 
HLA-DQA2 Antigen presentation (MHC II) T1D, RA 
HLA-DQB2 Antigen presentation (MHC II) RA  
HLA-DOB Antigen presentation (MHC II) SLE 
HLA-A Antigen presentation (MHC I) T1D, MS, PS, GD 
Chromosome 6  KLRK1 NK and T cell activation (NKG2D) T1D, RA, MS, CD, CeD, SLE 
MICA NKG2D Activating Ligand T1D, RA, UC, CeD, PS, SLE 
ULBP6 NKG2D Activating Ligand None 
ULBP3 NKG2D Activating Ligand None 
TNFA Proinflammatory cytokine RA, MS, IBD, SLE 
Chromosome 12 Eos (IKZF4) Transcription factor in Treg cells T1D, SLE 
ERBB3 Proliferation and differentiation T1D, SLE 
SH2B3 Negative regulator of cytokine 
signalling via receptor tyrosine 
kinases and JAK signalling 
Allergies 
ALDH2  Antioxidant  RA 
Chromosome 21 AIRE Autoimmune regulator, selection 
of auto-reactive cells 
APECED, T1D, GV, HT  




ICOS Co-stimulation T1D, MS 
Chromosome 4 IL-21 Th17 and NK cell proliferation T1D, RA, CeD, PS 
IL-2 T and B cell proliferation T1D, RA, CeD, PS 
Chromosome 10 IL-2RA T-cell proliferation T1D, MS, GD, GV 
Chromosome 5 IL-13/IL-4 Th2 differentiation  Not defined 
Chromosome 7 IL-6 Inflammatory cytokine T1D, RA, CeD 
Chromosome 12 IL-26 T cell differentiation  MS 
IFNG Regulation of immune responses SLE 
Chromosome 16  SOCS1 STAT inhibitor, regulator of IFN-γ 
response 
T1D, CeD 
Chromosome 18 PTPN2 Phosphatase involved in cell 
signalling 
T1D, CeD 
Chromosome 11 PRDX5 Antioxidant enzyme with roles in 
inflammation 
MS 
IL-18 Proinflammatory cytokine that 
augments natural killer cell 
activity and stimulates IFNγ 
production in T-helper type I cells 
RA, SLE 
Chromosome 9 STX17 No known inflammatory role. It is 
involved in premature hair 
greying 
None 
Chromosome X Cxcr3 Chemokine receptor  RA, T1D, PS, SLE 
Chromosome 4 Cxcl9 Chemoattractant for lymphocytes RA, T1D, PS, SLE 
Cxcl10 Chemokine: Monocyte, NK and T 
cell stimulation 
RA, T1D, PS, SLE 
Cxcl11 Chemokine: Chemotaxis of 
activated T cells 
RA, T1D, PS, SLE 
Chromosome 2 ACOXL/BCL2L11 Apoptosis, Autophagy regulation T1D, IgA Nephropathy, 
primary sclerosing 
cholangitis 
Chromosome 11 GARP (LRRC32) Treg differentiation and activity IBD, Allergies 
N.B.*: Inheritance of these genes means inheritance of susceptibility for developing the 
disease.  The majority of these genes are also involved in a variety of other autoimmune and 
inflammatory diseases, such as Type 1 Diabetes (T1D), Rheumatoid arthritis (RA), Systemic 
Lupus Erythematous (SLE), Psoriasis (PS), Multiple Sclerosis (MS), Crohn’s disease (CD), Celiac 
Disease (CeD), Inflammatory Bowel Disease (BID), Ulcerative Colitis (UC), Generalized Vitiligo 
(GV), Graves' Disease (GD), Hashimoto thyroiditis (HT) and allergies. Two genes encoding for 
NKG2D activating ligands, ULBP6 and ULBP3, have been associated only with alopecia areata 
phenotype. STX17, a gene involved in premature hair greying, is not linked to autoimmune 
responses, and instead may indicate intrinsic problems that can disrupt the hair cycle, with or 
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